Search

Your search keyword '"Gobom, Johan"' showing total 615 results
Start Over Author "Gobom, Johan"
615 results on '"Gobom, Johan"'

1. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

Author

Delvenne, Aurore, Vandendriessche, Charysse, Gobom, Johan, Burgelman, Marlies, Dujardin, Pieter, De Nolf, Clint, Tijms, Betty M., Teunissen, Charlotte E., Schindler, Suzanne E., Verhey, Frans, Ramakers, Inez, Martinez-Lage, Pablo, Tainta, Mikel, Vandenberghe, Rik, Schaeverbeke, Jolien, Engelborghs, Sebastiaan, De Roeck, Ellen, Popp, Julius, Peyratout, Gwendoline, Tsolaki, Magda, Freund-Levi, Yvonne, Lovestone, Simon, Streffer, Johannes, Bertram, Lars, Blennow, Kaj, Zetterberg, Henrik, Visser, Pieter Jelle, Vandenbroucke, Roosmarijn E., and Vos, Stephanie J. B.

Published
2024
Full Text
View/download PDF

3. Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology

Author

Therriault, Joseph, Woo, Marcel S., Salvadó, Gemma, Gobom, Johan, Karikari, Thomas K., Janelidze, Shorena, Servaes, Stijn, Rahmouni, Nesrine, Tissot, Cécile, Ashton, Nicholas J., Benedet, Andréa Lessa, Montoliu-Gaya, Laia, Macedo, Arthur C., Lussier, Firoza Z., Stevenson, Jenna, Vitali, Paolo, Friese, Manuel A., Massarweh, Gassan, Soucy, Jean-Paul, Pascoal, Tharick A., Stomrud, Erik, Palmqvist, Sebastian, Mattsson-Carlgren, Niklas, Gauthier, Serge, Zetterberg, Henrik, Hansson, Oskar, Blennow, Kaj, and Rosa-Neto, Pedro

Published
2024
Full Text
View/download PDF

5. Optimal blood tau species for the detection of Alzheimer’s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study

Author

Montoliu-Gaya, Laia, Alosco, Michael L., Yhang, Eukyung, Tripodis, Yorghos, Sconzo, Daniel, Ally, Madeline, Grötschel, Lana, Ashton, Nicholas J., Lantero-Rodriguez, Juan, Sauer, Mathias, Gomes, Bárbara, Nilsson, Johanna, Brinkmalm, Gunnar, Sugarman, Michael A., Aparicio, Hugo J., Martin, Brett, Palmisano, Joseph N., Steinberg, Eric G., Simkin, Irene, Turk, Katherine W., Budson, Andrew E., Au, Rhoda, Farrer, Lindsay, Jun, Gyungah R., Kowall, Neil W., Stern, Robert A., Goldstein, Lee E., Qiu, Wei Qiao, Mez, Jesse, Huber, Bertrand Russell, Alvarez, Victor E., McKee, Ann C., Zetterberg, Henrik, Gobom, Johan, Stein, Thor D., and Blennow, Kaj

Published
2024
Full Text
View/download PDF

8. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Author

Jansen, Iris E., van der Lee, Sven J., Gomez-Fonseca, Duber, de Rojas, Itziar, Dalmasso, Maria Carolina, Grenier-Boley, Benjamin, Zettergren, Anna, Mishra, Aniket, Ali, Muhammad, Andrade, Victor, Bellenguez, Céline, Kleineidam, Luca, Küçükali, Fahri, Sung, Yun Ju, Tesí, Niccolo, Vromen, Ellen M., Wightman, Douglas P., Alcolea, Daniel, Alegret, Montserrat, Alvarez, Ignacio, Amouyel, Philippe, Athanasiu, Lavinia, Bahrami, Shahram, Bailly, Henri, Belbin, Olivia, Bergh, Sverre, Bertram, Lars, Biessels, Geert Jan, Blennow, Kaj, Blesa, Rafael, Boada, Mercè, Boland, Anne, Buerger, Katharina, Carracedo, Ángel, Cervera-Carles, Laura, Chene, Geneviève, Claassen, Jurgen A. H. R., Debette, Stephanie, Deleuze, Jean-Francois, de Deyn, Peter Paul, Diehl-Schmid, Janine, Djurovic, Srdjan, Dols-Icardo, Oriol, Dufouil, Carole, Duron, Emmanuelle, Düzel, Emrah, Fladby, Tormod, Fortea, Juan, Frölich, Lutz, García-González, Pablo, Garcia-Martinez, Maria, Giegling, Ina, Goldhardt, Oliver, Gobom, Johan, Grimmer, Timo, Haapasalo, Annakaisa, Hampel, Harald, Hanon, Olivier, Hausner, Lucrezia, Heilmann-Heimbach, Stefanie, Helisalmi, Seppo, Heneka, Michael T., Hernández, Isabel, Herukka, Sanna-Kaisa, Holstege, Henne, Jarholm, Jonas, Kern, Silke, Knapskog, Anne-Brita, Koivisto, Anne M., Kornhuber, Johannes, Kuulasmaa, Teemu, Lage, Carmen, Laske, Christoph, Leinonen, Ville, Lewczuk, Piotr, Lleó, Alberto, de Munain, Adolfo López, Lopez-Garcia, Sara, Maier, Wolfgang, Marquié, Marta, Mol, Merel O., Montrreal, Laura, Moreno, Fermin, Moreno-Grau, Sonia, Nicolas, Gael, Nöthen, Markus M., Orellana, Adelina, Pålhaugen, Lene, Papma, Janne M., Pasquier, Florence, Perneczky, Robert, Peters, Oliver, Pijnenburg, Yolande A. L., Popp, Julius, Posthuma, Danielle, Pozueta, Ana, Priller, Josef, Puerta, Raquel, Quintela, Inés, Ramakers, Inez, Rodriguez-Rodriguez, Eloy, Rujescu, Dan, Saltvedt, Ingvild, Sanchez-Juan, Pascual, Scheltens, Philip, Scherbaum, Norbert, Schmid, Matthias, Schneider, Anja, Selbæk, Geir, Selnes, Per, Shadrin, Alexey, Skoog, Ingmar, Soininen, Hilkka, Tárraga, Lluís, Teipel, Stefan, Tijms, Betty, Tsolaki, Magda, Van Broeckhoven, Christine, Van Dongen, Jasper, van Swieten, John C., Vandenberghe, Rik, Vidal, Jean-Sébastien, Visser, Pieter J., Vogelgsang, Jonathan, Waern, Margda, Wagner, Michael, Wiltfang, Jens, Wittens, Mandy M. J., Zetterberg, Henrik, Zulaica, Miren, van Duijn, Cornelia M., Bjerke, Maria, Engelborghs, Sebastiaan, Jessen, Frank, Teunissen, Charlotte E., Pastor, Pau, Hiltunen, Mikko, Ingelsson, Martin, Andreassen, Ole A., Clarimón, Jordi, Sleegers, Kristel, Ruiz, Agustín, Ramirez, Alfredo, Cruchaga, Carlos, Lambert, Jean-Charles, and van der Flier, Wiesje

Published
2022
Full Text
View/download PDF

10. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

Author

Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.

Published
2022
Full Text
View/download PDF

11. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis

Author

Jiang, Richeng, Smailovic, Una, Haytural, Hazal, Tijms, Betty M., Li, Hao, Haret, Robert Mihai, Shevchenko, Ganna, Chen, Gefei, Abelein, Axel, Gobom, Johan, Frykman, Susanne, Sekiguchi, Misaki, Fujioka, Ryo, Watamura, Naoto, Sasaguri, Hiroki, Nyström, Sofie, Hammarström, Per, Saido, Takaomi C., Jelic, Vesna, Syvänen, Stina, Zetterberg, Henrik, Winblad, Bengt, Bergquist, Jonas, Visser, Pieter Jelle, and Nilsson, Per

Published
2022
Full Text
View/download PDF

12. Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia

Author

Sogorb-Esteve, Aitana, Nilsson, Johanna, Swift, Imogen J., Heller, Carolin, Bocchetta, Martina, Russell, Lucy L., Peakman, Georgia, Convery, Rhian S., van Swieten, John C., Seelaar, Harro, Borroni, Barbara, Galimberti, Daniela, Sanchez-Valle, Raquel, Laforce, Jr., Robert, Moreno, Fermin, Synofzik, Matthis, Graff, Caroline, Masellis, Mario, Tartaglia, Maria Carmela, Rowe, James B., Vandenberghe, Rik, Finger, Elizabeth, Tagliavini, Fabrizio, Santana, Isabel, Butler, Chris R., Ducharme, Simon, Gerhard, Alexander, Danek, Adrian, Levin, Johannes, Otto, Markus, Sorbi, Sandro, Le Ber, Isabelle, Pasquier, Florence, Gobom, Johan, Brinkmalm, Ann, Blennow, Kaj, Zetterberg, Henrik, and Rohrer, Jonathan D.

Published
2022
Full Text
View/download PDF

14. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

Author

Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.

Published
2022
Full Text
View/download PDF

17. Post‐GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3

Author

Panyard, Daniel J., primary, Reus, Lianne M., additional, Ali, Muhammad, additional, Liu, Jihua, additional, Deming, Yuetiva K., additional, Lu, Qiongshi, additional, Kollmorgen, Gwendlyn, additional, Carboni, Margherita, additional, Wild, Norbert, additional, Visser, Pieter J., additional, Bertram, Lars, additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, Gobom, Johan, additional, Western, Dan, additional, Sung, Yun Ju, additional, Carlsson, Cynthia M., additional, Johnson, Sterling C., additional, Asthana, Sanjay, additional, Cruchaga, Carlos, additional, Tijms, Betty M., additional, Engelman, Corinne D., additional, and Snyder, Michael P., additional

Published
2024
Full Text
View/download PDF

19. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease.

Author

Delvenne, Aurore, Gobom, Johan, Schindler, Suzanne E., Kate, Mara ten, Reus, Lianne M., Dobricic, Valerija, Tijms, Betty M., Benzinger, Tammie L. S., Cruchaga, Carlos, Teunissen, Charlotte E., Ramakers, Inez, Martinez‐Lage, Pablo, Tainta, Mikel, Vandenberghe, Rik, Schaeverbeke, Jolien, Engelborghs, Sebastiaan, Roeck, Ellen De, Popp, Julius, Peyratout, Gwendoline, and Tsolaki, Magda

Published
2024
Full Text
View/download PDF

20. Tau protein profiling in tauopathies: a human brain study.

Author

Lantero-Rodriguez, Juan, Camporesi, Elena, Montoliu-Gaya, Laia, Gobom, Johan, Piotrowska, Diana, Olsson, Maria, Burmann, Irena Matečko, Becker, Bruno, Brinkmalm, Ann, Burmann, Björn M., Perkinton, Michael, Ashton, Nicholas J., Fox, Nick C., Lashley, Tammaryn, Zetterberg, Henrik, Blennow, Kaj, and Brinkmalm, Gunnar

Subjects
TAU proteins, TAUOPATHIES, PROGRESSIVE supranuclear palsy, ALZHEIMER'S disease, PATHOLOGICAL physiology, HUMAN experimentation
Abstract

Abnormal accumulation of misfolded and hyperphosphorylated tau protein in brain is the defining feature of several neurodegenerative diseases called tauopathies, including Alzheimer's disease (AD). In AD, this pathological change is reflected by highly specific cerebrospinal fluid (CSF) tau biomarkers, including both phosphorylated and non-phosphorylated variants. Interestingly, despite tau pathology being at the core of all tauopathies, CSF tau biomarkers remain unchanged in certain tauopathies, e.g., progressive supranuclear palsy (PSP), Pick's disease (PiD), and corticobasal neurodegeneration (CBD). To better understand commonalities and differences between tauopathies, we report a multiplex assay combining immunoprecipitation and high-resolution mass spectrometry capable of detecting and quantifying peptides from different tau protein isoforms as well as non-phosphorylated and phosphorylated peptides, including those carrying multiple phosphorylations. We investigated the tau proteoforms in soluble and insoluble fractions of brain tissue from subjects with autopsy-confirmed tauopathies, including sporadic AD (n = 10), PSP (n = 11), PiD (n = 10), and CBD (n = 10), and controls (n = 10). Our results demonstrate that non-phosphorylated tau profiles differ across tauopathies, generally showing high abundance of microtubule-binding region (MTBR)-containing peptides in insoluble protein fractions compared with controls; the AD group showed 12–72 times higher levels of MTBR-containing aggregates. Quantification of tau isoforms showed the 3R being more abundant in PiD and the 4R isoform being more abundant in CBD and PSP in the insoluble fraction. Twenty-three different phosphorylated peptides were quantified. Most phosphorylated peptides were measurable in all investigated tauopathies. All phosphorylated peptides were significantly increased in AD insoluble fraction. However, doubly and triply phosphorylated peptides were significantly increased in AD even in the soluble fraction. Results were replicated using a validation cohort comprising AD (n = 10), CBD (n = 10), and controls (n = 10). Our study demonstrates that abnormal levels of phosphorylation and aggregation do indeed occur in non-AD tauopathies, however, both appear pronouncedly increased in AD, becoming a distinctive characteristic of AD pathology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.

Author

Nilsson, Johanna, Binette, Alexa Pichet, Palmqvist, Sebastian, Brum, Wagner S, Janelidze, Shorena, Ashton, Nicholas J, Spotorno, Nicola, Stomrud, Erik, Gobom, Johan, Zetterberg, Henrik, Brinkmalm, Ann, Blennow, Kaj, and Hansson, Oskar

Subjects
NEURODEGENERATION, CEREBROSPINAL fluid, MILD cognitive impairment, ALZHEIMER'S disease, CEREBRAL atrophy
Abstract

Synaptic dysfunction and degeneration is likely the key pathophysiology for the progression of cognitive decline in various dementia disorders. Synaptic status can be monitored by measuring synaptic proteins in CSF. In this study, both known and new synaptic proteins were investigated and compared as potential biomarkers of synaptic dysfunction, particularly in the context of Alzheimer's disease (AD). Seventeen synaptic proteins were quantified in CSF using two different targeted mass spectrometry assays in the prospective Swedish BioFINDER-2 study. The study included 958 individuals, characterized as having mild cognitive impairment (MCI, n = 205), AD dementia (n = 149) and a spectrum of other neurodegenerative diseases (n = 171), in addition to cognitively unimpaired individuals (CU, n = 443). Synaptic protein levels were compared between diagnostic groups and their associations with cognitive decline and key neuroimaging measures (amyloid-β-PET, tau-PET and cortical thickness) were assessed. Among the 17 synaptic proteins examined, 14 were specifically elevated in the AD continuum. SNAP-25, 14-3-3 zeta/delta, β-synuclein, and neurogranin exhibited the highest discriminatory accuracy in differentiating AD dementia from controls (areas under the curve = 0.81–0.93). SNAP-25 and 14-3-3 zeta/delta also had the strongest associations with tau-PET, amyloid-β-PET and cortical thickness at baseline and were associated with longitudinal changes in these imaging biomarkers [β(standard error, SE) = −0.056(0.0006) to 0.058(0.005), P < 0.0001]. SNAP-25 was the strongest predictor of progression to AD dementia in non-demented individuals (hazard ratio = 2.11). In contrast, neuronal pentraxins were decreased in all neurodegenerative diseases (except for Parkinson's disease), and NPTX2 showed the strongest associations with subsequent cognitive decline [longitudinal Mini-Mental State Examination: β(SE) = 0.57(0.1), P ≤ 0.0001; and mPACC: β(SE) = 0.095(0.024), P ≤ 0.001] across the AD continuum. Interestingly, utilizing a ratio of the proteins that displayed higher levels in AD, such as SNAP-25 or 14-3-3 zeta/delta, over NPTX2 improved the biomarkers' associations with cognitive decline and brain atrophy. We found 14-3-3 zeta/delta and SNAP-25 to be especially promising as synaptic biomarkers of pathophysiological changes in AD. Neuronal pentraxins were identified as general indicators of neurodegeneration and associated with cognitive decline across various neurodegenerative dementias. Cognitive decline and brain atrophy were best predicted by ratios of SNAP-25/NPTX2 and 14-3-3 zeta/delta/NPTX2. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathy.

Author

van den Berg, Emma, Kersten, Iris, Brinkmalm, Gunnar, Johansson, Kjell, de Kort, Anna M., Klijn, Catharina J. M., Schreuder, Floris H. B. M., Gobom, Johan, Stoops, Erik, Portelius, Erik, Gkanatsiou, Eleni, Zetterberg, Henrik, Blennow, Kaj, Kuiperij, H. Bea, and Verbeek, Marcel M.

Subjects
CEREBRAL amyloid angiopathy, LIQUID chromatography-mass spectrometry, PEPTIDES, ALZHEIMER'S disease, BIOMARKERS
Abstract

Brain amyloid‐β (Aβ) deposits are key pathological hallmarks of both cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Microvascular deposits in CAA mainly consist of the Aβ40 peptide, whereas Aβ42 is the predominant variant in parenchymal plaques in AD. The relevance in pathogenesis and diagnostic accuracy of various other Aβ isoforms in CAA remain understudied. We aimed to investigate the biomarker potential of various Aβ isoforms in cerebrospinal fluid (CSF) to differentiate CAA from AD pathology. We included 25 patients with probable CAA, 50 subjects with a CSF profile indicative of AD pathology (AD‐like), and 23 age‐ and sex‐matched controls. CSF levels of Aβ1‐34, Aβ1‐37, Aβ1‐38, Aβ1‐39, Aβ1‐40, and Aβ1‐42 were quantified by liquid chromatography mass spectrometry. Lower CSF levels of all six Aβ peptides were observed in CAA patients compared with controls (p = 0.0005–0.03). Except for Aβ1‐42 (p = 1.0), all peptides were decreased in CAA compared with AD‐like subjects (p = 0.007–0.03). Besides Aβ1‐42, none of the Aβ peptides were decreased in AD‐like subjects compared with controls. All Aβ peptides combined differentiated CAA from AD‐like subjects better (area under the curve [AUC] 0.84) than individual peptide levels (AUC 0.51–0.75). Without Aβ1‐42 in the model (since decreased Aβ1‐42 served as AD‐like selection criterion), the AUC was 0.78 for distinguishing CAA from AD‐like subjects. CAA patients and AD‐like subjects showed distinct disease‐specific CSF Aβ profiles. Peptides shorter than Aβ1‐42 were decreased in CAA patients, but not AD‐like subjects, which could suggest different pathological mechanisms between vascular and parenchymal Aβ accumulation. This study supports the potential use of this panel of CSF Aβ peptides to indicate presence of CAA pathology with high accuracy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Identifying Optimal Blood Tau Epitopes for the Detection of Alzheimer’s Disease Neuropathology: An Immunoprecipitation Mass Spectrometry and Autopsy Study

Author

Montoliu‐Gaya, Laia, primary, Alosco, Michael L, additional, Yhang, Eukyung, additional, Tripodis, Yorghos, additional, Ashton, Nicholas J., additional, Rodriguez, Juan Lantero, additional, Aparicio, Hugo J, additional, Sugarman, Michael A, additional, Ally, Madeline, additional, Martin, Brett M, additional, Palmisano, Joseph N, additional, Steinberg, Eric, additional, Simkin, Irene, additional, Turk, Katherine W, additional, Budson, Andrew E, additional, Au, Rhoda, additional, Farrer, Lindsay A., additional, Jun, Gyungah R, additional, Kowall, Neil W, additional, Stern, Robert A, additional, Killiany, Ronald J, additional, Goldstein, Lee E, additional, Qiu, Wei Qiao, additional, Huber, Bertrand R., additional, Mez, Jesse B., additional, McKee, Ann C., additional, Zetterberg, Henrik, additional, Gobom, Johan, additional, and Stein, Thor D., additional

Published
2023
Full Text
View/download PDF

27. Optimal combination of CSF phosphorylated‐tau forms to predict Alzheimer’s disease pathological burden as measured by PET

Author

Collij, Lyduine E., primary, Gobom, Johan, additional, Janelidze, Shorena, additional, Ossenkoppele, Rik, additional, Smith, Ruben, additional, Strandberg, Olof, additional, Stomrud, Erik, additional, Palmqvist, Sebastian, additional, Mattsson‐Carlgren, Niklas, additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, and Hansson, Oskar, additional

Published
2023
Full Text
View/download PDF

29. Targeted proteomic search reveals new actors in the synaptic and lysosomal dysfunction in genetic FTD, a GENFI study.

Author

Weiner, Sophia, primary, Malichova, Frederika, additional, Simrén, Joel, additional, Sauer, Mathias, additional, Swift, Imogen J, additional, Heller, Carolin, additional, Knowles, Kathryn, additional, van Swieten, John C., additional, Jiskoot, Lize C., additional, Seelaar, Harro, additional, Moreno, Fermin, additional, Sanchez‐Valle, Raquel, additional, Laforce, Robert, additional, Graff, Caroline, additional, Masellis, Mario, additional, Tartaglia, Carmela, additional, Rowe, James B., additional, Borroni, Barbara, additional, Finger, Elizabeth, additional, Synofzik, Matthis, additional, Galimberti, Daniela, additional, Vandenberghe, Rik, additional, de Mendonça, Alexandre, additional, Butler, Christopher, additional, Gerhard, Alexander, additional, Ducharme, Simon, additional, Ber, Isabelle Le, additional, Tiraboschi, Pietro, additional, Santana, Isabel, additional, Pasquier, Florence, additional, Levin, Johannes, additional, Otto, Markus, additional, Sorbi, Sandro, additional, Blennow, Kaj, additional, Zetterberg, Henrik, additional, Rohrer, Jonathan D., additional, Gobom, Johan, additional, and Esteve, Aitana Sogorb, additional

Published
2023
Full Text
View/download PDF

31. Profiling amyloid‐β peptides as diagnostic biomarkers for cerebral amyloid angiopathy

Author

van den Berg, Emma, primary, de Kort, Anna M., additional, Kersten, Iris, additional, Brinkmalm, Gunnar, additional, Johansson, Kjell, additional, Marques, Tainá M., additional, Jäkel, Lieke, additional, Gobom, Johan, additional, Stoops, Erik, additional, Portelius, Erik, additional, Gkanatsiou, Eleni, additional, Abdo, Wilson F., additional, Rasing, Ingeborg, additional, Voigt, Sabine, additional, Koemans, Emma A., additional, Kaushik, Kanishk, additional, Warren, Andrew D., additional, Greenberg, Steven M., additional, Terwindt, Gisela M., additional, Wermer, Marieke J.H., additional, Klijn, Catharina J.M., additional, Schreuder, Floris H.B.M., additional, Zetterberg, Henrik, additional, Blennow, Kaj, additional, Kuiperij, H. Bea, additional, and Verbeek, Marcel M., additional

Published
2023
Full Text
View/download PDF

33. Developing a mass spectrometric assay to measure granulin peptides in CSF for progranulin‐associated frontotemporal dementia

Author

Swift, Imogen J, primary, Weiner, Sophia, additional, Sauer, Mathias, additional, Nilsson, Johanna, additional, van Swieten, John C., additional, Jiskoot, Lize C., additional, Seelaar, Harro, additional, Moreno, Fermin, additional, Sánchez‐Valle, Raquel, additional, Laforce, Robert, additional, Graff, Caroline, additional, Masellis, Mario, additional, Tartaglia, Carmela, additional, Rowe, James B., additional, Borroni, Barbara, additional, Finger, Elizabeth, additional, Synofzik, Matthis, additional, Galimberti, Daniela, additional, Vandenberghe, Rik, additional, de Mendonça, Alexandre, additional, Butler, Christopher, additional, Gerhard, Alexander, additional, Ducharme, Simon, additional, Ber, Isabelle Le, additional, Tiraboschi, Pietro, additional, Santana, Isabel, additional, Pasquier, Florence, additional, Levin, Johannes, additional, Otto, Markus, additional, Sorbi, Sandro, additional, Brinkmalm, Ann, additional, Zetterberg, Henrik, additional, Rohrer, Jonathan D., additional, Esteve, Aitana Sogorb, additional, and Gobom, Johan, additional

Published
2023
Full Text
View/download PDF

37. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

Author

Konijnenberg, Elles, Tijms, Betty M., Gobom, Johan, Dobricic, Valerija, Bos, Isabelle, Vos, Stephanie, Tsolaki, Magda, Verhey, Frans, Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Frölich, Lutz, Lovestone, Simon, Streffer, Johannes, Bertram, Lars, Blennow, Kaj, Teunissen, Charlotte E., Veerhuis, Robert, Smit, August B., Scheltens, Philip, Zetterberg, Henrik, and Visser, Pieter Jelle

Published
2020
Full Text
View/download PDF

38. Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus

Author

Weiner, Sophia, primary, Junkkari, Antti, additional, Sauer, Mathias, additional, Luikku, Antti, additional, Rauramaa, Tuomas, additional, Kokkola, Tarja, additional, Herukka, Sanna-Kaisa, additional, Blennow, Kaj, additional, Zetterberg, Henrik, additional, Leinonen, Ville, additional, and Gobom, Johan, additional

Published
2023
Full Text
View/download PDF

39. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies

Author

Montoliu-Gaya, Laia, primary, Benedet, Andréa L., additional, Tissot, Cécile, additional, Vrillon, Agathe, additional, Ashton, Nicholas J., additional, Brum, Wagner S., additional, Lantero-Rodriguez, Juan, additional, Stevenson, Jenna, additional, Nilsson, Johanna, additional, Sauer, Mathias, additional, Rahmouni, Nesrine, additional, Brinkmalm, Gunnar, additional, Lussier, Firoza Z., additional, Pascoal, Tharick A., additional, Skoog, Ingmar, additional, Kern, Silke, additional, Zetterberg, Henrik, additional, Paquet, Claire, additional, Gobom, Johan, additional, Rosa-Neto, Pedro, additional, and Blennow, Kaj, additional

Published
2023
Full Text
View/download PDF

41. SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease.

Author

Weiner, Sophia, Sauer, Mathias, Brinkmalm, Gunnar, Constantinescu, Julius, Constantinescu, Radu, Gomes, Bárbara Fernandes, Becker, Bruno, Nellgård, Bengt, Dalla, Keti, Galasko, Douglas, Zetterberg, Henrik, Blennow, Kaj, and Gobom, Johan

Abstract

INTRODUCTION: Secernin‐1 (SCRN1) is a neuronal protein that co‐localizes with neurofibrillary tangles in Alzheimer's disease (AD), but not with tau inclusions in corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), or Pick's disease. METHODS: We measured SCRN1 concentration in cerebrospinal fluid (CSF) using a novel mass spectrometric parallel reaction monitoring method in three clinical cohorts comprising patients with neurochemically characterized AD (n = 25) and controls (n = 28), clinically diagnosed Parkinson's disease (PD; n = 38), multiple system atrophy (MSA; n = 31), PSP (n = 20), CBD (n = 8), healthy controls (n = 37), and neuropathology‐confirmed AD (n = 47). RESULTS: CSF SCRN1 was significantly increased in AD (P < 0.01, fold change = 1.4) compared to controls (receiver operating characteristic area under the curve = 0.78) but not in CBD, PSP, PD, or MSA. CSF SCRN1 positively correlated with CSF total tau (R = 0.78, P = 1.1 × 10−13), phosphorylated tau181 (R = 0.64, P = 3.2 × 10−8), and Braak stage and negatively correlated with Mini‐Mental State Examination score. DISCUSSION: CSF SCRN1 is a candidate biomarker of AD, reflecting tau pathology. HIGHLIGHTS: We developed a parallel reaction monitoring assay to measure secernin‐1 (SCRN1) in cerebrospinal fluid (CSF).CSF SCRN1 was increased in Alzheimer's disease compared to healthy controls.CSF SCRN1 remained unchanged in Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or corticobasal degeneration compared to controls.CSF SCRN1 correlated strongly with CSF phosphorylated tau and total tau.CSF SCRN1 increased across Braak stages and negatively correlated with Mini‐Mental State Examination score. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

Author

van den Berg, Emma, primary, Nilsson, Johanna, additional, Kersten, Iris, additional, Brinkmalm, Gunnar, additional, de Kort, Anna M., additional, Klijn, Catharina J.M., additional, Schreuder, Floris H.B.M., additional, Jäkel, Lieke, additional, Gobom, Johan, additional, Portelius, Erik, additional, Zetterberg, Henrik, additional, Brinkmalm, Ann, additional, Blennow, Kaj, additional, Kuiperij, H. Bea, additional, and Verbeek, Marcel M., additional

Published
2023
Full Text
View/download PDF

43. Protein disulfide isomerases as CSF biomarkers for the neuronal response to tau pathology

Author

Wolzak, Kimberly, primary, Vermunt, Lisa, additional, Campo, Marta del, additional, Jorge‐Oliva, Marta, additional, van Ziel, Anna Maria, additional, Li, Ka Wan, additional, Smit, August B., additional, Chen‐Ploktkin, Alice, additional, Irwin, David J., additional, Lemstra, Afina W., additional, Pijnenburg, Yolande, additional, van der Flier, Wiesje, additional, Zetterberg, Henrik, additional, Gobom, Johan, additional, Blennow, Kaj, additional, Visser, Pieter Jelle, additional, Teunissen, Charlotte E., additional, Tijms, Betty M., additional, and Scheper, Wiep, additional

Published
2023
Full Text
View/download PDF

44. Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood

Author

Andreasson, Ulf, primary, Gobom, Johan, additional, Delatour, Vincent, additional, Auclair, Guy, additional, Noam, Yoav, additional, Lee, Stephen, additional, Wen, Jason, additional, Jeromin, Andreas, additional, Arslan, Burak, additional, Maceski, Aleksandra, additional, Willemse, Eline, additional, Zetterberg, Henrik, additional, Kuhle, Jens, additional, and Blennow, Kaj, additional

Published
2023
Full Text
View/download PDF

46. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

Author

Delvenne, Aurore, Gobom, Johan, Tijms, Betty, et al, Popp, Julius, University of Zurich, and Delvenne, Aurore

Subjects
2806 Developmental Neuroscience, 2738 Psychiatry and Mental Health, 2728 Neurology (clinical), 10054 Clinic for Psychiatry, Psychotherapy, and Psychosomatics, 2804 Cellular and Molecular Neuroscience, 610 Medicine & health, 2717 Geriatrics and Gerontology, 2719 Health Policy, 2713 Epidemiology
Published
2023
Full Text
View/download PDF

47. Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders

Author

Nilsson, Johanna, primary, Constantinescu, Julius, additional, Nellgård, Bengt, additional, Jakobsson, Protik, additional, Brum, Wagner S., additional, Gobom, Johan, additional, Forsgren, Lars, additional, Dalla, Keti, additional, Constantinescu, Radu, additional, Zetterberg, Henrik, additional, Hansson, Oskar, additional, Blennow, Kaj, additional, Bäckström, David, additional, and Brinkmalm, Ann, additional

Published
2022
Full Text
View/download PDF

48. Simultaneous Mass Spectrometric quantification of multiple p‐tau species in plasma – findings along the Alzheimer´s disease continuum

Author

Montoliu‐Gaya, Laia, primary, Benedet, Andréa Lessa, additional, Brum, Wagner Scheeren, additional, Vrillon, Agathe, additional, Ashton, Nicholas J., additional, Rodriguez, Juan Lantero, additional, Brinkmalm, Gunnar, additional, Nilsson, Johanna, additional, Karikari, Thomas K, additional, Kern, Silke, additional, Zetterberg, Henrik, additional, Paquet, Claire, additional, Rosa‐Neto, Pedro, additional, Gobom, Johan, additional, and Blennow, Kaj, additional

Published
2022
Full Text
View/download PDF

49. Multi‐modal Analysis and Modeling of Human Neurodegenerative Disease to Reveal Disease Mechanisms and Biomarkers

Author

Marsh, Samuel E, primary, Murphy, Sarah, additional, Kamath, Tushar, additional, Gazestani, Vahid, additional, Therrien, Martine, additional, Dolan, Michael John, additional, Jereb, Sasa, additional, Reyes, Miguel, additional, Gobom, Johan, additional, Clish, Clary, additional, Hacohen, Nir, additional, Zetterberg, Henrik, additional, Leinonen, Ville, additional, Macosko, Evan, additional, and Stevens, Beth, additional

Published
2022
Full Text
View/download PDF

50. CSF Proteome Changes Depend on APOE Genotype in Prodromal AD

Author

Vromen, Eleonora M., primary, Wesenhagen, Kirsten E. J., additional, van der Kant, Rik, additional, Gobom, Johan, additional, Scheltens, Philip, additional, Teunissen, Charlotte E., additional, Dobricic, Valerija, additional, Bertram, Lars, additional, Zetterberg, Henrik, additional, Visser, Pieter Jelle, additional, and Tijms, Betty M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results